✦ LIBER ✦

Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone)

✍ Scribed by Wannesson, Luciano; Bargetzi, Mario; Cairoli, Anne; Cerutti, Alessandra; Heim, Dominik; Hess, Urs; Lerch, Erika; Pabst, Thomas; Renner, Christoph; Samaras, Panagiotis; Zucca, Emanuele

Book ID: 120259125
Publisher: Informa plc
Year: 2012
Tongue: English
Weight: 255 KB
Volume: 54
Category: Article
ISSN: 1042-8194
DOI: 10.3109/10428194.2012.702903

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The cyclophosphamide, vincristine, predn

The cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, and procarbazine (COPBLAM-I) regimen for intermediate-grade non-Hodgkin's lymphoma. Long term follow-up in 51 patients

✍ Ofer Shpilberg; Jacob Shif; Angela Chetrit; Bracha Ramot; Isaac Ben-Bassat 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 434 KB 👁 2 views

Background. Cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, and procarbazine (COP-BLAM-I) is a second generation combination chemotherapy for intermediate-grade non-Hodgkin's lymphoma (NHL). Since the first report by Laurence et al. in 1982, only a few series were reported on the

Biweekly COP-BLAM (cyclophosphamide, vin

Biweekly COP-BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for intermediate-grade non-Hodgkin's lymphoma

✍ Nozomi Niitsu; Masanori Umeda 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 428 KB

Hybrid chemotherapy consisting of cyclop

Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced hodgkin disease

✍ Silvia Montoto; Mireia Camós; Armando López-Guillermo; Francesc Bosch; Francisco 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB 👁 1 views

## BACKGROUND. Combination chemotherapy, including hybrid regimens, is the standard treatment for patients with advanced Hodgkin disease (HD). Although a prolonged complete response (CR) is achieved in up to 70 -80% of patients, long term complications, such as secondary leukemia, are of concern. C

Chemotherapy of Hodgkin’s lymphoma with

Chemotherapy of Hodgkin’s lymphoma with alternating cycles of COPP (cyclophosphamide, vincristin, procarbazine, prednisone) and ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine). Results of the HD1 and HD3 trials of the German Hodgkin Study Group

✍ V. Diehl; M. Pfreundschuh; M. Löffler; U. Rühl; E. Hiller; H. Gerhartz; W. Wilma 📂 Article 📅 1989 🏛 Springer US 🌐 English ⚖ 598 KB

Cyclophosphamide, doxorubicin, vincristi

Cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy and radiotherapy for stage I intermediate or high grade non-Hodgkin's lymphomas: results of a strategy that adapts radiotherapy dose to the response after chemotherapy

✍ Augustinus D.G Krol; Henriëtte W.A Berenschot; Dew Doekharan; Sonja Henzen-Logma 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 97 KB

Four versus six courses of a dose-escala

Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation : Early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma

✍ Nobert Schmitz; Marita Kloess; Marcel Reiser; Wolfgang E. Berdel; Bernd Metzner; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 252 KB